Followers | 3178 |
Posts | 154136 |
Boards Moderated | 4 |
Alias Born | 06/03/2011 |
Tuesday, February 28, 2023 3:03:24 PM
Recent COEP News
- Form 8-K - Current report • Edgar (US Regulatory) • 07/31/2024 09:00:33 PM
- Coeptis Therapeutics Closes on $4.3 Million of Series A Preferred Offering • PR Newswire (US) • 06/20/2024 12:47:00 PM
- Coeptis Therapeutics' Dr. Colleen Delaney to Present at Allogeneic Cell Therapies Summit 6th Annual Meeting • PR Newswire (US) • 05/30/2024 12:47:00 PM
- Coeptis Therapeutics to Present its Universal Allogeneic SNAP-CAR NK Cell Therapy at the ISCT 2024 • PR Newswire (US) • 05/08/2024 12:47:00 PM
- Coeptis Therapeutics Announces Poster Data Presentation at American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting • PR Newswire (US) • 05/02/2024 12:47:00 PM
- Coeptis Therapeutics Congratulates Alexander Deiters, Professor at the University of Pittsburgh, on Receiving the 2024 Chancellor's Distinguished Research Award • PR Newswire (US) • 04/02/2024 12:47:00 PM
- Coeptis Therapeutics Adds Autoimmune Indications to Exclusive License Agreement with University of Pittsburgh for SNAP-CAR T and SNAP-CAR NK • PR Newswire (US) • 02/26/2024 02:00:00 PM
- Coeptis Therapeutics to Pursue Phase 2 Program Using Proprietary First-in-Class Allogeneic NK Cell Therapy for the Treatment of Viral Infections • PR Newswire (US) • 02/07/2024 12:30:00 PM
- Coeptis Therapeutics President and CEO Issues Letter to Shareholders Highlighting 2023 Accomplishments and Outlook for 2024 • PR Newswire (US) • 01/04/2024 12:30:00 PM
- Coeptis Therapeutics Announces Research Demonstrating the Potential of SNAP-CAR T-cells to Reduce Tumor Burden and Growth in HER2 and CD20 Expressing Cancers Will be Presented at SITC 2023 • PR Newswire (US) • 10/31/2023 01:01:00 PM
- Coeptis Therapeutics Announces $2 Million Private Placement • PR Newswire (US) • 10/24/2023 12:30:00 PM
- Coeptis Therapeutics Expands License Agreement with University of Pittsburgh to Include SNAP-CAR NK Cell Technology • PR Newswire (US) • 10/11/2023 11:30:00 AM
- Coeptis Therapeutics to Participate in Panel at the BioFlorida Conference Discussing Emerging Cell and Gene Therapies • PR Newswire (US) • 10/09/2023 01:15:00 PM
- Coeptis Therapeutics Announces Research Involving SNAP-CAR Accepted for Presentation at the Society for Immunotherapy of Cancer's 38th Annual Meeting • PR Newswire (US) • 10/04/2023 11:30:00 AM
- Coeptis Therapeutics to Present at the 2023 Cell & Gene Meeting on the Mesa • PR Newswire (US) • 09/27/2023 11:30:00 AM
- Coeptis Therapeutics Provides Safety and Dosing Update from Phase 1 Trials Investigating DVX201 in Relapsed/Refractory AML or High Risk MDS and Hospitalized COVID-19 Infection • PR Newswire (US) • 09/14/2023 11:30:00 AM
- Coeptis Therapeutics Announces Deverra Therapeutics Has Received Two Life Science Start-Up and Development Awards and Associated Grant from Washington's Cancer Research Endowment • PR Newswire (US) • 09/11/2023 11:30:00 AM
- Coeptis Therapeutics Appoints Colleen Delaney, MD, as Chief Scientific and Medical Officer • PR Newswire (US) • 08/30/2023 05:00:00 PM
- Coeptis Therapeutics Completes Exclusive License for Allogeneic Immuno-Oncology Platform and Clinical Stage Assets from Deverra Therapeutics • PR Newswire (US) • 08/17/2023 11:30:00 AM
Maybacks Global Entertainment and ZEASN Technology Private Ltd. Sign Global Licensing Agreement • AHRO • Aug 8, 2024 7:00 AM
SANUWAVE Will Host a Conference Call on August 13, 2024 at 8:30 AM (ET) to Present Q2 Financial Results • SNWV • Aug 8, 2024 6:59 AM
Kona Gold Beverage Inc. Signs Letter of Intent with Bemax, Inc. to Sell Kona Gold, LLC • BMXC • Aug 7, 2024 10:00 AM
Btab Ecommerce Group, Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • BBTT • Aug 7, 2024 9:00 AM
Hydromer, Inc. Announces Preliminary Unaudited Second Quarter 2024 Financial Results and Provides Business Update • HYDI • Aug 7, 2024 8:52 AM
North Bay Resources Announces Mt. Vernon Gold Mine Startup, Sierra County, California • NBRI • Aug 5, 2024 9:00 AM